• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Alnylam Pharmaceuticals - Articles and news items

Genzyme opts into Alnylam’s ALN-AT3 haemophilia programme

Industry news / 1 October 2015 / Victoria White

Genzyme has elected to opt into the programme for development and potential future commercialisation of ALN-AT3 in territories outside of North America and Western Europe…

Alnylam receives Orphan Drug Designation for revusiran for the treatment of ATTR amyloidosis

Industry news / 21 May 2015 / Victoria White

The FDA has granted Orphan Drug Designation to Alnylam’s revusiran for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis)…